Q-omics provides the consensus-scored TBC1D3F profile across patient tissues and cancer cell-line models. TBC1D3F expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D3F is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, TBC1D3F RNA expression shows 5,093 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KIRP, and STAD as cancer lineages where TBC1D3F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D3F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D3F survival associations across molecular data types. TBC1D3F RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D3F RNA expression–survival associations across cancer types. High TBC1D3F expression shows unfavorable associations in KIRC, LIHC, ACC, HNSC and PAAD, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D3F RNA expression.
This table summarizes TBC1D3F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TBC1D3F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D3F shows higher tumor expression in KIRP, LUSC, KIRC and THCA. The KIRP box plot shows higher TBC1D3F RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .014).
This table shows molecular features associated with TBC1D3F in patient tissues and cancer cell lines. In patient samples, TBC1D3F shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D3F RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
